Adept.missouri.edu

MU-ADEPT Level 3: Advanced Training Resources
Resources
The ATTC's Medication-Assisted Treatment with Special Populations online training,
developed for both non-physician treatment providers and physicians, is designed to enhance Medication-Assisted
professionals' knowledge and skills related to reaching and educating the special populations about MAT and increasing the use of MAT among minority populations.
Treatment
A compilation of essays by individuals supported by Medication-Assisted Treatment in long- term recovery developed in partnership with Faces & Voices of Recovery and the National
Alliance for Medication Assisted Recovery.
Database/manual The Psychotherapeutic Medications Booklet and Database are designed as a "desk-top
reference" of medications commonly used to treat individuals with alcohol, drug, and mental health conditions. This searchable database offers is intended to provide a basic understanding of medication dose, frequency, side effects, emergency conditions, abuse potential, cautions, and considerations for pregnant women.
Managing Opioid Abuse, Dependence, and Addiction in a Primary Care Setting, a
presentation by Jean J. Bonhomme MD, MPH, assistant professor, Morehouse School of Medicine’s Department of Psychiatry, provides an introduction to opioid abuse for primary care professionals Prescribers’ Clinical Support System for Opioid Therapies (PCSS-O) is a collaborative project that includes: American Academy of Addiction Psychiatry, American Dental Association,
American Medical Association, American Osteopathic Academy of Addiction Medicine,
American Psychiatric Association, American Society for Pain Management Nursing, and
International Nurses Society on Addictions. Site includes online modules (PowerPoints) and
archived webinars.
Management of
A Review of Considerations in the Assessment and Treatment of Pain and Risk for Opioid
chronic non-
Misuse by By Elinore F. McCance-Katz, MD, PhD, Medical Director, PCSS-O
terminal pain with
GroupHealth Chronic Opioid Therapy (COT) Safety Guideline For Patients With Chronic Non- http://www.ghc.org/al -sites/guidelines/chronicOpioid.pdf
Cancer Pain
SAMHSA’s Advisory: An Introduction to Extended-Release Injectable Naltrexone for the
Treatment of People with Opioid Dependence overviews extended-release injectable
Management of
naltrexone (Vivitrol), a treatment for people with opioid dependence, and discusses how it differs from other medication-assisted treatments, safety concerns, and consumers most likely opioid addiction
Medication-Assisted Treatment for Opioid Addiction: Friends and Families is a useful
resource developed by SAMHSA for friends and families of individuals struggling with SAMHSA’s Treatment Improvement Protocol (TIP) 40: Clinical Guidelines for the Use of
Buprenorphine in the Treatment of Opioid Addiction provides information that physicians can
use to make practical and informed decisions about the use of buprenorphine to treat opioid
addiction.
KAP Keys Based on TIP 40 Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction - includes: Dosage Forms of Buprenorphine Available in the United States
(as of July 2004), Drug Interactions, Components of a Complete Substance Abuse Assessment,
Recommended Baseline Laboratory Evaluation of Patients Who Are Addicted to Opioids, Signs
of Opioid Intoxication and Withdrawal, Staging and Grading Opioid Withdrawal, Assessing
Appropriateness for Buprenorphine Treatment, Treatment Protocols (Induction, Day 2
Forward, Stabilization), Patient Management
SAMHSA’s TIP 43: Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs discusses MAT use in addiction treatment programs for opioid dependence
Quick Guide Based on TIP 43 Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs
KAP Keys Based on TIP 43 Medication-Assisted Treatment for Opioid Addiction in Opioid
Treatment Programs - includes: Information Obtained About and Provided to Patients During
Screening and Admission, Pharmacotherapeutic Medications for Opioid Addiction Treatment,
Possible Side Effects of Opioid Agonist and Partial Agonist Therapy, Reported Drug Interactions
With Methadone, Strategies To Prevent or Minimize Harmful Drug Interactions in MAT,
Medications/Substances That Alter Opioid Medication Levels in the Body, Criteria for Take-
Home Medications and Maximum Take-Home Dose, Patient Counseling in MAT, Common
Topics for Patient Educational Sessions in MAT, Characteristics of a Treatment Plan and a
Multidisciplinary Team, Associated Medical Problems, Hepatitis C Evaluation Flowchart, Cutoff
Concentrations and Detection Times for Substances of Abuse, Urine Drug Testing Guidelines,
Common Immunoassays Used in Drug Testing, Frequently Used Substance Combinations and
Common Reasons for Use, Common Medical and Obstetrical Compli cations Among Pregnant
Women, Laboratory Tests for Pregnant Women Who Are Opioid Addicted
Review of Opioids and Treatment of Opioid Dependence. By Elinore F. McCance-Katz, MD,
Patient Education The Facts about Naltrexone for Treatment of Opioid Dependence patient education brochure Brochure
Training/Presentati NIDA/ATTC Blending Initiative - Buprenorphine Treatment: Training for Multidisciplinary
Addiction Professionals
NIDA/ATTC Blending Initiative -Prescription Opioid Addiction Treatment Study (POATS)
TIP 54: Managing Chronic Pain in Adults With or in Recovery from Substance Use Disorders equips clinicians with practical guidance and tools for treating chronic pain in adults with
substance use disorders. This TIP includes information and resources on patient assessment, Treating pain in a
talking with patients about medication supply, addiction behaviors, opiod misuse measures, patient on chronic
opioid replacement
therapy (methadone
or buprenorphine)
Withdrawal and
TIP 45 Detoxification and Substance Abuse Treatment educates clinicians about detoxification
detoxification
Quick Guide Based on TIP 45 Detoxification and Substance Abuse Treatment
KAP KEYS Based on TIP 45 Detoxification and Substance Abuse Treatment - includes:
Intoxication and Withdrawal (Fact Facts, Symptoms, Management) From Cocaine, Methamphetamine, and Other Stimulants, Alcohol, Herion and Other Opioids, Cannabis, Other Drugs; Initial Evaluation Domains, Recommended Areas for Assessment to Determine Appropriate Rehabilitation Plans, Commonly Abused Inhalants (Fact Facts, Symptoms, Management) Manual, Booklet, See TIP 45 Detoxification and Substance Abuse Treatment Products
Pharmacotherapy of Pocket Cards
alcohol withdrawal
Mayo-Smith et al. for the Working Group on the Management of Alcohol Withdrawal Delirium, Practice Guidelines Committee, American Society of Addiction Medicine. Management of
Alcohol Withdrawal Delirium: An Evidence-Based Practice Guideline, Arch Intern Med.
2004;164:1405-1412
Saitz, R. Introduction to Alcohol Withdrawal. Alc Hlth Res World. 1998;22:5-12. (includes
CIWA assessment tool and dosing guidelines) Manual, Booklet, See TIP 45 Detoxification and Substance Abuse Treatment Products
Pharmacotherapy of Pocket Cards
opioid withdrawal
Manual, Booklet, See TIP 40 Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid
Pocket Cards
Addiction Products
Manual, Booklet, See TIP 43 Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment
Pocket Cards
Programs Products
NIDA/ATTC Blending Initiative - Short-Term Opioid Withdrawal Using Buprenorphine:
Findings and Strategies from a NIDA Clinical Trials Network (CTN) Study
SAMHSA’s TIP 49: Incorporating Alcohol Pharmacotherapies into Medical Practice provides
Pharmacotherapy of
guidance on implementing alcohol medications into routine medical practice.
alcohol dependence
Quick Guide For Physicians Based on TIP 49 Incorporating Alcohol Pharmacotherapies Into Medical Practice
KAP Keys Based on TIP 49 Incorporating Alcohol Pharmacotherapies Into Medical Practice - includes: medication facts, dosing, side effects, adverse reactions and their management;
Patient Management
NIAAA's Medical Management Treatment Manual: A Clinical Guide for Researchers and
Clinicians Providing Pharmacotherapy for Alcohol Dependence (Generic Version; 2010
edition) by Helen M. Pettinati, PhD and Margaret E. Mattson, PhD Management of
SAMHSA's Pharmacologic Guidelines for Treating Individuals with Post-Traumatic Stress
anxiety disorders in
Disorder and Co-Occurring Opioid Use Disorders offers guidelines for medication-assisted
patients with
treatment for individuals with post-traumatic stress disorder (PTSD) and co-occurring opioid use disorders. Covers screening, concomitant treatment, pharmacotherapy, and multiple addictions
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC181171/pdf/i1523- Arikian, SR, Gorman, JM. A Review of the Diagnosis, Pharmacologic Treatment, and Economic 5998-003-03-0110.pdf
Aspects of Anxiety Disorders. Prim Care Companion J Clin Psychiatry. 2001; 3(3): 110–117.
Management of
SBIRT and Tobacco Training Module is a webinar developed by HealthTeamWorks for the
tobacco addiction,
Colorado SBIRT project that provides practical information for providers seeking to implement including
SBIRT and tobacco screening into routine practice. In addition to overviews of tobacco screenings and SBIRT, the 1-hour webinar includes information on financing, brief pharmacotherapies
interventions, and referrals to treatment. 52 minutes.
Treating Tobacco Use and Dependence: 2008 Update, sponsored by the Public Health Service,
Reference Guide, includes new, effective clinical treatments for tobacco dependence that have become available since the 2000 Guideline was published. This update wil make an important contribution to the quality of care in the United States and to the health of the American people.
Basic and Advanced Website
Mid-Atlantic ATTC’s Motivational Interviewing Website
skil s for effective
motivational
interviewing
Mid-Atlantic ATTC’s On-line course: "Foundations of Motivational Interviewing - Part I" 10
Mid-Atlantic ATTC’s On-line course: "Foundations of Motivational Interviewing - Part II” 10 contact hours:
TIP 35 manual: Enhancing Motivation for Change in Substance Abuse Treatment
Quick Guide Based on TIP 35 Enhancing Motivation for Change in Substance Abuse
Treatment
KAP KEYS Based on TIP 35 Enhancing Motivation for Change in Substance Abuse Treatment - includes: the FRAMES approach, Appropriate Motivational Strategies for Each Stage of Change,
Ten Effective Catalysts for Change, Four Types of Client Resistance, Change Plan Worksheet,
Deciding To Change,
Working with
TIP 24 A Guide to Substance Abuse Services for Primary Care Clinicians - Recommends
counselors: A team
guidelines for primary care clinicians to follow in caring for patients with alcohol abuse and drug abuse problems. Discusses screening, assessment, brief intervention, medication-assisted approach to
treatment, and legal issues of patient confidentiality.
addressing
substance use
disorders
KAP KEYS Based on TIP 24 A Guide to Substance Abuse Services for Primary Care Clinicians - includes: Interview Approaches Based on the Patient's Readiness for Behavioral Change,
Michigan Alcoholism Screening Test, DSM-IV Diagnostic Criteria for Substance Abuse, TWEA K
Test (alcohol screener for pregnant women)
Integrated
SAMHSA’s TIP 42: Substance Abuse Treatment for Persons With Co-Occurring Disorders
treatment for co-
provides substance abuse providers with updated information on co-occurring substance use occurring substance
and mental disorders and advances in treatment for these individuals. TIP 42 discusses terminology, assessment, and treatment strategies and models.
abuse and mental
illness
KAP KEYS Based on TIP 42 Substance Abuse Treatment for Persons With Co-Occurring
Disorders - includes: Assessment for Co-Occurring Disorders, Motivational Enhancement
Approaches, Engagement Interventions, Key Questions in a Suicide Risk Review, Residential
Interventions, Borderline Personality Disorder–Step Work Handout, Antisocial Thinking-Error
Work
SAMHSA's General Principles for the Use of Pharmacological Agents To Treat Individuals
With Co-Occurring Mental and Substance Use Disorders provides general principles to assist in the planning, delivery, and evaluation of pharmacologic approaches to support the recovery of individuals with co-occurring mental and substance use disorders.
NIAAA's Adolescent Development and Alcohol Use by Vivian B. Faden, Ph.D., Acting Director, http://www.niaaa.nih.gov/publications/presentations-and-
Office of Science Policy and Communications, and Patricia A. Powell, Ph.D., Chief, Science
Policy Branch. National Institute on Alcohol Abuse and Alcoholism, NIH. December 9, 2008 Substance misuse
and chronic disease
(e.g., HTN)
NIAAA's Alcohol Screening and Brief Intervention for Youth: A PRACTITIONER’S
GUIDE introduces a simple, quick, empirically derived tool for identifying youth at risk for
alcohol-related problems. If your organization manages the health and well-being of children Substance misuse in
and adolescents ages 9–18 years, this Guide is for you. It has been produced in col aboration with the American Academy of Pediatrics, clinical researchers, and health practitioners.
adolescents
NIDA/ATTC Blending Initiative - Buprenorphine Treatment for Young Adults
SAMHSA's Fetal Alcohol Spectrum Disorder Center for Excellence - The FASD Center is a
Fetal alcohol
Federal initiative devoted to preventing and treating FASD. This Website provides information syndrome
and resources about FASD. We also provide materials you can use to raise awareness about prevention,
FASD. Additionally, The Center is dedicated to providing training, technical assistance, and recognition,
management
SAMHSA's FASD Center for Excellence Curriculum for Addiction Professionals (CAP): Level 1, 6-module free, self-paced course. "This curriculum was developed as a joint project of the
Substance Abuse and Mental Health Services Administration (SAMHSA) Fetal Alcohol Spectrum Disorders (FASD) Center for Excellence and the National Organization on Fetal Alcohol Syndrome (NOFAS). This knowledge-based course provides an overview of historical findings related to alcohol use by pregnant women, identification and diagnosis of fetal alcohol spectrum disorders, prevention and treatment methods, and legal issues. The course includes six competencies that can be taken at your own pace. After completing all six competencies, you may download and print a certificate of completion." CDC's National Organization on Fetal Alcohol Syndrome (NOFAS) website
CDC Fetal Alcohol Syndrome: Guidelines for Referral and Diagnosis. This report provides
diagnostic guidelines for FAS and information about referrals, services for people with FASDs and their families, and strategies for screening and advising women about risky drinking SAMHSA's FASD Center for Excel ence FASD: The Basics is an educational presentation created to provide the latest and most accurate information on Fetal Alcohol Spectrum Disorders
(FASD). It covers the history of FASD discovery, examines cause and effects of FASD, and
discusses the methods and resources for diagnosis, treatment and –most importantly– the
prevention of FASD.
Management of
SAMHSA's TIP 53 Addressing Viral Hepatitis in People with Substance Use Disorders Assists http://store.samhsa.gov/product/TIP-53-Addressing-Viral-
Hepatitis and
behavioral health professionals who treat people with substance abuse problems in Hepatitis-in-People-With-Substance-Use-Disorders/SMA11-4656 Substance Use
understanding the implications of a diagnosis of hepatitis. Discusses screening, diagnosis, and referrals and explains how to evaluate a program's hepatitis practices. Disorders

Source: https://adept.missouri.edu/Portals/0/MU-ADEPT_AdvancedTrainingResources.heatherATTC12.pdf